Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Qiagen ( (QGEN) ) is now available.
Qiagen N.V. announced a managerial transaction involving Lawrence Rosen, a member of the supervisory body, who received 24,968 common shares through the release of Restricted Stock Units due to not standing for re-appointment to the Supervisory Board. This transaction, linked to share option programs, involved a net settlement where 12,098 shares were received after covering related expenses, potentially impacting the company’s shareholding structure and investor relations.
The most recent analyst rating on (QGEN) stock is a Hold with a $42.50 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. operates in the biotechnology industry, providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company focuses on enabling customers to gain valuable insights from the building blocks of life, primarily through innovative technologies and products.
Average Trading Volume: 1,487,438
Technical Sentiment Signal: Buy
Current Market Cap: $10.28B
See more data about QGEN stock on TipRanks’ Stock Analysis page.